Jane Street Group LLC Sells 183,577 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Jane Street Group LLC cut its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 41.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 262,608 shares of the biopharmaceutical company's stock after selling 183,577 shares during the period. Jane Street Group LLC owned approximately 0.20% of Dynavax Technologies worth $3,354,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DVAX. Russell Investments Group Ltd. boosted its position in Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 1,169 shares during the period. Smartleaf Asset Management LLC grew its stake in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 2,034 shares during the last quarter. GAMMA Investing LLC grew its stake in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock valued at $52,000 after buying an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Dynavax Technologies in the 4th quarter worth $71,000. Finally, Nisa Investment Advisors LLC lifted its position in Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after acquiring an additional 1,076 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on DVAX. The Goldman Sachs Group dropped their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. StockNews.com downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. JMP Securities cut their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Price Performance

DVAX stock traded up $0.16 during midday trading on Friday, reaching $9.67. 1,573,605 shares of the company's stock traded hands, compared to its average volume of 2,218,531. The company has a 50-day simple moving average of $11.87 and a two-hundred day simple moving average of $12.52. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 1-year low of $9.22 and a 1-year high of $14.63. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 53.72 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). The business had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.